|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:ATCCode
|
gptkb:N05AH03
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:CASNumber
|
gptkb:132539-06-1
|
|
gptkbp:color
|
yellow
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
21-54 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
IKHBVPDZYYGQTP-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C17H20N4S
|
|
gptkbp:hasSMILES
|
CN1CCN(C2=NC3=CC=CC=C3SC4=CC=CC=C42)CC1
|
|
gptkbp:hasUNII
|
7M546I6E82
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CHEMBL1540
|
|
gptkbp:indication
|
bipolar disorder
schizophrenia
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isPatentProtected
|
false
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
antipsychotic medication
|
|
gptkbp:meltingPoint
|
195-197°C
|
|
gptkbp:metabolism
|
hepatic (CYP1A2, CYP2D6)
|
|
gptkbp:molecularWeight
|
312.43
|
|
gptkbp:name
|
Olanzapine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
93%
|
|
gptkbp:PubChem_CID
|
4585
D00425
CHEBI:7737
DB00334
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
|
|
gptkbp:sideEffect
|
weight gain
dyslipidemia
somnolence
hyperglycemia
|
|
gptkbp:synonym
|
gptkb:Zyprexa
LY170053
2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
|
|
gptkbp:target
|
gptkb:Histamine_H1_receptor
Alpha-1 adrenergic receptor
Dopamine D2 receptor
Muscarinic acetylcholine receptor M1
Serotonin 5-HT2A receptor
|
|
gptkbp:bfsParent
|
gptkb:retinol
|
|
gptkbp:bfsLayer
|
5
|